Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98410 | 0.86 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Hydrochloric Acid SCHEMBL10584588 | 0.85 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Water SCHEMBL27625510 | 0.85 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL607047 | 0.82 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL2176024 | 0.82 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28213460 | 0.81 | PDE3A (0.45) | SLC29A1 | |
| Pyrophosphoric Acid SCHEMBL2800166 | 0.79 | P2RY6 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL425422 | 0.78 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Triphosphate SCHEMBL28074755 | 0.77 | P2RY6 (0.49) | P2RY14P2RY2P2RY4P2RY6 | |
| SCHEMBL28176484 | 0.77 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272945-A1 | USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS | AB SCIENCE (FR) | 2015-10-01 | — | — | US | claimed |
| EP-2903616-A1 | USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS | AB Science (FR) | 2015-08-12 | — | — | EP | claimed |
| WO-2014053650-A1 | USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS | AB SCIENCE (FR) | 2014-04-10 | — | — | WO | claimed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | claimed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | claimed |
| WO-2008065193-A1 | COMBINATION PRODUCT CONTAINING N-DESMETHYLSERTRALINE, OR A SALT THEREOF, AND AN ANTINEOPLASTIC AGENT FOR THE TREATMENT OF CANCER | CEREP (FR) | 2008-06-05 | — | — | WO | claimed |
| US-20220175919-A1 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER | NATIONAL CANCER CENTER (JP) | 2022-06-09 | — | — | US | disclosed |
| US-10238649-B2 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | AB SCIENCE (FR) | 2019-03-26 | — | — | US | disclosed |
| US-20180236068-A1 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-08-23 | — | — | US | disclosed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| US-20160022812-A1 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER | NATIONAL CANCER CENTER (JP) | 2016-01-28 | — | — | US | disclosed |
| CN-104968347-A | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | AB SCIENCE | 2015-10-07 | — | — | CN | disclosed |
| US-20150272945-A1 | USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS | AB SCIENCE (FR) | 2015-10-01 | — | — | US | disclosed |
| WO-2014053650-A1 | USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS | AB SCIENCE (FR) | 2014-04-10 | — | — | WO | disclosed |
| EP-2578233-A1 | THERAPEUTIC AGENT FOR PANCREATIC CANCER | National Cancer Center (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| EP-2117531-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB Science (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008084103-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008065193-A1 | COMBINATION PRODUCT CONTAINING N-DESMETHYLSERTRALINE, OR A SALT THEREOF, AND AN ANTINEOPLASTIC AGENT FOR THE TREATMENT OF CANCER | CEREP (FR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238649-B2 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | KIT, CPA3, CTSK | SLC28A1 3579/4885SLC28A2 3346/4885SLC29A1 3411/4885 |
| US-20150272945-A1 | USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS | KIT, CPA3, CTSK | SLC28A1 3579/4885SLC28A2 3346/4885SLC29A1 3411/4885 |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | ERBB2, ERBB3, ERBB4 | SLC28A1 838/4885SLC28A2 699/4885SLC29A1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.